PARAMSTAT LIMITED
Company number 07884377 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Commercial Credit Assessment: PARAMSTAT LIMITED
1. Credit Opinion: CONDITIONAL
Reasoning: Paramstat demonstrates an exceptionally strong balance sheet with negligible leverage and outstanding liquidity. The company has accumulated significant cash reserves over a decade of profitable trading. However, the 2024 financial year shows a deterioration — shareholders' funds declined by £43,100 (from £689,538 to £646,438), indicating a trading loss after years of consistent growth. Additionally, the biotechnology R&D sector carries inherent uncertainty around revenue sustainability, and the accounts are filleted (no P&L disclosed), limiting visibility into the nature and cause of this loss. Approval is recommended but conditional upon understanding the 2024 loss and confirming it is non-recurring rather than a structural decline.
2. Financial Strength
Balance Sheet Summary (FY2024): - Total Assets: £663,092 - Total Liabilities: £16,894 - Net Assets / Shareholders' Funds: £646,438 - Share Capital: £100 (minimal equity base; growth funded through retained earnings)
Gearing & Leverage: The company is effectively ungeared. Total liabilities represent just 2.5% of total assets. There is no long-term debt. The liability position is dominated by trade creditors (£244) and taxation/social security (£14,151). This is an exceptionally conservative capital structure.
Asset Composition: - Cash: £583,635 (88% of total assets) - Debtors: £79,457 (12% of total assets) - Tangible Fixed Assets: £240 (negligible)
This is an asset-light, cash-rich business model typical of knowledge-based R&D operations. The minimal fixed asset base (£240 net book value after depreciation) means there is little collateral value, but this is irrelevant given the cash position.
Equity Trajectory:
| Year | Shareholders' Funds | YoY Change |
|---|---|---|
| 2015 | £162,021 | — |
| 2016 | £198,462 | +£36,441 |
| 2017 | £353,902 | +£155,440 |
| 2018 | £411,781 | +£57,879 |
| 2019 | £420,225 | +£8,444 |
| 2020 | £419,034 | -£1,191 |
| 2021 | £463,192 | +£44,158 |
| 2022 | £571,420 | +£108,228 |
| 2023 | £689,538 | +£118,118 |
| 2024 | £646,438 | -£43,100 |
Nine consecutive years of growth followed by a reversal in 2024. The cumulative retained profits remain substantial, but the loss warrants investigation.
Assessment: Balance sheet strength is exceptional. The company could absorb significant losses before approaching any solvency concern.
3. Cash Flow Assessment
Liquidity Position: - Current Assets: £663,092 - Current Liabilities: £16,894 - Current Ratio: 39.2:1 - Net Current Assets (Working Capital): £646,198
This is an extraordinarily strong liquidity position. The company could settle all current liabilities approximately 39 times over from current assets alone.
Cash Trend:
| Year | Cash | YoY Change |
|---|---|---|
| 2020 | £417,103 | — |
| 2021 | £463,091 | +£45,988 |
| 2022 | £597,521 | +£134,430 |
| 2023 | £742,794 | +£145,273 |
| 2024 | £583,635 | -£159,159 |
Cash decreased by £159,159 in 2024. Given the retained earnings decline of £43,100, the larger cash reduction suggests either capital expenditure, increased debtors, or a combination. The accounts show debtors increased by £47,649 (from £31,808 to £79,457), with other debtors rising from £8,093 to £38,102 — a £30,009 increase that requires explanation. The remaining cash reduction is attributable to the trading loss and corporation tax settlement (taxation liabilities fell from £81,428 to £14,151, indicating approximately £67,000 of tax was paid).
Debtors Quality Concern: Trade debtors increased from £23,715 to £41,355 (74% increase), while other debtors increased from £8,093 to £38,102 (371% increase). The other debtors balance warrants clarification — it could represent intercompany balances, prepayments, or R&D tax credit receivables, but the magnitude and growth rate require confirmation.
Working Capital Cycle: The company appears to operate with minimal trade creditor days (only £244 outstanding) and moderate trade debtor levels. This suggests prompt payment to suppliers and reasonable collection practices, though the debtor increase may indicate slowing collections or larger project-based invoicing.
Assessment: Liquidity is outstanding and poses no concern for debt service capability. The cash drawdown in 2024 is partially explained by tax settlement and debtor growth, but the underlying trading loss needs to be understood.
4. Monitoring Points
| Metric | Current Value | Concern Threshold | Rationale |
|---|---|---|---|
| Cash Position | £583,635 | Below £300,000 | Early warning if cash continues to decline at similar rate |
| Retained Earnings Trend | £646,338 | Two consecutive years of decline | Would indicate structural rather than one-off issue |
| Other Debtors | £38,102 | Above £20,000 without satisfactory explanation | Clarify nature — if irrecoverable, write-off risk exists |
| Trade Debtors Days | Estimate ~60 days | Above 90 days | Monitor for collection deterioration |
| Corporation Tax Liability | £14,151 | Significant reduction from prior year | Confirms profitability was historically strong; future tax liability indicates ongoing profitability expectations |
| Revenue/Profitability | Not disclosed (filleted accounts) | Any further losses | Request management accounts to assess trading performance |
Key Questions for Management: 1. What caused the 2024 loss after years of profitable growth? Is this a one-off investment phase, project delay, or market deterioration? 2. What constitutes "other debtors" at £38,102, and what is the expected recoverability? 3. What is the company's revenue recognition model for biotech R&D — milestone payments, grants, or service income? 4. Are there any contingent liabilities, litigation, or contractual commitments not reflected on the balance sheet? 5. What is the strategic plan for the accumulated cash reserves — R&D investment, dividend extraction, or acquisition?
Sector Considerations: Biotechnology R&D (SIC 72110) is characterised by long development cycles, uncertain revenue streams, and dependence on intellectual property. While this company's cash reserves provide substantial buffer, the sector risk means income can be lumpy and unpredictable. Any credit facility should factor in potential for extended periods without revenue.